|Ran Nussbaum – Chairman
Ran is a managing partner and co-founder of The Pontifax Group. Pontifax operates six different funds with more than 75 portfolio companies worldwide. In addition, Pontifax has established more than 19 startups since it was incorporated in 2005.
Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Currently Ran sits on the board of many of Pontifax’s portfolio companies, including Keros Therapeutics (as Chairman of the Board), Eloxx Pharmaceuticals Inc (NASDAQ: ELOX), UroGen Pharma (NASDAQ: URGN), Prevail Therapeutics (NASDAQ: PRVL) and Lutris Pharma. Previously, Ran served on the board of Kite Pharma (sold to Gilead) and cCEM Therapeutics (sold to Merck), as Chairman of the Board of OCON and NasVax, and as CEO of Spearhead and Biomedix.
|Jasbir Seehra, Ph.D.
Jasbir Seehra is the founding CEO of Keros Therapeutics. Jas worked with the academic founders and Pontifax in putting together the strategy and in-licensing of the founding technology. Jas brings more than 30 years of scientific, strategic and operational experience in Biotech industry.
Prior to Keros, Dr. Seehra was the CSO at Ember Therapeutics, founded by Third Rock Ventures. In 2003, Jas co-founded Acceleron Pharma, focused on biologics inhibiting the TGFb superfamily and served as CSO to the end of 2010. Jas hired the research team that discovered multiple products and manufacturing teams and oversaw the discovery and development of multiple products targeting muscle strength, bone loss and anemia. As founder and member of the executive team, Jas helped raise more than $200M capital from venture fund and corporate partnerships with Celgene and Shire.
| Julius KnowlesJay Knowles is a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare. Partners was founded by Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH), the two principal teaching hospitals of the Harvard Medical School. At Partners, Jay focuses on creating and helping to grow drug discovery companies.
Prior to Partners, Jay was CEO of X-BODY Biosciences (acquired by Juno). Previously, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President of Novalar Pharmaceuticals, a specialty pharmaceutical company that brought a drug from idea stage through the clinic and onto the market. Before that, he was Vice President, Business Development, at Novacea and at Structural Genomix, and Director, Research and Development Planning at Vertex Pharmaceuticals. Jay earned his MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He is a member of the board of directors at Aurigene, represents Partners on the boards of Abcuro, Keros, Swan and Tilos, and is a board observer for LTI (Lysosomal Therapeutics Inc.) and Akouos.
|Alon Lazarus, Ph.D.
Alon Lazarus is a Biotech Investment Manager for Arkin Holdings’ Pharma Division. He is a member of the Board of several of its pharmaceutical companies, including Oncorus, Lutris Pharma, Redpin Therapeutics and Explore Bio.
Tomer has served as a member of our board of directors since January 2020. Mr. Kariv has served as Managing Partner and Co-Founder of The Pontifax Group, or Pontifax, a group of Israeli-based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies, since December 2004.
Mr. Kariv currently serves on the boards of Eloxx Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc., and he previously served on the boards of 89bio, Inc., Arno Therapeutics, Inc., Check-Cap Ltd., Macrocure Ltd. and VBI Vaccines Inc. Mr. Kariv also serves as a member of the boards of several private life sciences companies. Mr. Kariv received a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.
Zafi Avnur Ms. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche.
Ms. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche.